Publication Name	World Journal of Orthopedics
Manuscript ID	8914
Country	United States

Received	2014-01-11 14:42
Peer-Review Started	2014-01-11 17:15
To Make the First Decision	2014-01-23 17:19
Return for Revision	2014-02-09 21:21
Revised	2014-02-28 01:53
Second Decision	2014-06-20 11:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-06-20 12:08
Articles in Press	2014-06-20 13:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-08-11 08:39
Publish the Manuscript Online	2014-08-20 20:37

ISSN	2218-5836 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Rheumatology
Manuscript Type	Topic Highlights
Article Title	Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives
Manuscript Source	Invited Manuscript
All Author List	Charles J Malemud and David E Blumenthal
Funding Agency and Grant Number	Funding Agency Grant Number Genentech/Roche Group and the Case Western Reserve University School of Medicine Visual Sciences Research Core P30 EY-011373
Corresponding Author	Charles J Malemud, PhD, Department of Medicine, Division of Rheumatic Diseases, The Arthritis Research Laboratory, Foley Medical Building, 2061 Cornell Road, Cleveland, OH 44106-5076, United States. cjm4@cwru.edu
Key Words	Clinical trials; Protein kinase; Signal transduction; Small molecule inhibitor; Rheumatoid arthritis
Core Tip	Signal transduction is a regulator of gene expression in cells. Janus kinase/Signal Transducers and Activators of Transcription (JAK/STAT) signaling is activated by pro-inflammatory cytokines which contributes to immune-mediated inflammation in rheumatoid arthritis. Medicinal chemistry was employed to develop JAK small molecule inhibitors for determining their clinical efficacy in active rheumatoid arthritis patients. Tofacitinib, a JAK small molecule inhibitor, is now generally used to treat moderate to severe rheumatoid arthritis patients who have not adequately responded to disease-modifying anti-rheumatic drugs or various biologic agents. The clinical efficacy of JAK small molecule inhibitors provides the impetus for future drug discovery targeted at other signal transduction pathways in rheumatoid arthritis.
Publish Date	2014-08-20 20:37
Citation	Malemud CJ, Blumenthal DE. Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives. World J Orthop 2014; 5(4): 496-503
URL	http://www.wjgnet.com/2218-5836/full/v5/i4/496.htm
DOI	http://dx.doi.org/10.5312/wjo.v5.i4.496

Full Article (PDF)	WJO-5-496.pdf
Full Article (Word)	WJO-5-496.doc
Manuscript File	8914-Review.doc
Answering Reviewers	8914-Answering reviewers.pdf
Biostatistics Review Certificate	Biostatistician_Review_Report_20140111032838.doc
Copyright License Agreement	8914-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20140111032750.doc
Non-Native Speakers of English Editing Certificate	Editing_Certificate_20140111033023.doc
Peer-review Report	8914-Peer review(s).pdf
Scientific Misconduct Check	8914-CrossCheck.jpg
Scientific Editor Work List	8914-Scientific editor work list.pdf